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Abstract
Background: Antimicrobial resistance generates a huge health and economic burden and has the potential to
become the leading cause of death globally, but its underlying drivers are yet to be fully described. The association
between a microbe’s exposure to antimicrobials and subsequent development of, or selection for, resistance is well
documented, as are the exacerbating microbial and human factors. However, the nature and extent of this risk, and
how it varies by antimicrobial class and duration of treatment, is poorly defined. The goal of our systematic review and
network meta-analysis is to determine the relationship between the duration of antimicrobial exposure and selection
for resistance. We will use macrolides as the antimicrobial class of interest and Streptococcus pneumoniae carriage as an
indicator organism. Our secondary outcomes include duration of symptoms, risk of treatment failure and recurrence,
and descriptions of resistance mechanisms.
Methods: We will conduct a systematic review, selecting studies if they are published randomised controlled trials (RCTs)
which report the relationship between taking a macrolide for any indication and incidence of resistant Streptococcus
pneumoniae in patients of any age group. We will use a predefined search strategy to identify studies meeting these
eligibility criteria in MEDLINE, Embase, Global Health and the Cochrane Central Register of RCTs. Two authors will
independently screen titles and abstracts, review the full texts and undertake data extraction. We will use the Cochrane
Collaboration’s tool to assess the quality of included RCTs. If feasible, we will perform pair-wise meta-analysis modelling to
determine the relationship between the duration of macrolide treatment and development of macrolide resistant
Streptococcus pneumoniae. If the identified studies meet the assumptions for a network meta-analysis (NMA), we will
additionally model this relationship using indirect comparisons. Our protocol utilises reporting guidance by Preferred
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and the extensions for protocols (PRISMA-P) and
network meta-analyses (PRISMA for NMA). Our review will also report to these standards.
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Discussion: Establishing the relationship between the duration of antimicrobial exposure and development of, or selection
for, resistance will inform the design of antimicrobial prescriptions, treatment guidelines and the behaviour of both
physicians and patients. This work will therefore be a strong contribution towards the full realisation of current antimicrobial
resistance stewardship strategies.
Systematic review registration: PROSPERO CRD42018089275
Keywords: Antimicrobial resistance, Network meta-analysis, Macrolides, Streptococcus pneumoniae, Carriage, Treatment
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Background
Antimicrobials—organic or synthetic molecules with
cytotoxic or cytostatic abilities against microbes—are
one of the greatest medical discoveries [1]. Unfortu-
nately, their usefulness is limited by the inherent genetic
capacity of microbes to rapidly develop, transfer and ac-
quire resistance-causing mutations [2, 3]. Unnecessary
prescription in medical settings, as well as extensive
agricultural use, contributes substantially to overall anti-
biotic drug pressure globally [4–6]. The current era is
characterised by sharply declining investment from the
pharmaceutical industry in the development of effective
new antimicrobials; far fewer new compounds are devel-
oped annually now than during the 1990s [7].
In 2016, antimicrobial resistance became one of only
four health topics ever to be discussed at the United Na-
tions General Assembly [8], reflecting its huge health and
economic burden [9, 10]. Drug resistance is projected to
become the leading cause of death by 2050 [11].
The development of antimicrobial resistance is, to
some extent, inevitable. Billions of doses of antibiotics
are taken globally each year. Each human hosts a micro-
biome of approximately 3.8 × 1013 bacteria [12], and
there is spontaneous (i.e. unselected) drug-resistance
within this microbiome at a frequency as high as 10−4
mutations, depending upon the type of antimicrobial
[13–15]. Under drug pressure, resistance can then be
amplified and transmitted through a variety of mecha-
nisms [2]. Despite these risks, use of single-drug regi-
mens remains standard practice for many conditions,
because they are often sufficient to cure the patient and
they reduce immediate costs and adverse events.
There is unambiguous evidence that the development
of, or selection for, resistance occurs following anti-
microbial exposure [4, 16–18]. The duration of treat-
ment that is necessary for the development of, or
selection for, resistance is poorly defined, however. This
may differ by the resistance mechanism; for example,
the unmasking of any resistant organisms generated dur-
ing previous treatment periods may rapidly occur follow-
ing a brief exposure to antimicrobials, while de novo
generation may require longer durations. Better quantifi-
cation of this relationship will inform prescription
design, guidelines and behaviour, all of which are key
factors in effective antimicrobial resistance control strat-
egies [19].
To explore this relationship and derive high-quality
evidence, it is necessary to choose an antimicrobial or
class of antimicrobials with which patients are treated,
an indicator organism in which drug resistance develops
and a uniform method for assessing resistance. Macro-
lides are one of the most prescribed antimicrobials in
clinical practice [20, 21], which act by inhibiting bacter-
ial protein synthesis [22]. Streptococcus pneumoniae, a
major aetiology of clinical illness [23–26], also harm-
lessly colonises the upper respiratory tract, creating a
window for the assessment of circulating serotypes and
resistance patterns. Streptococcus pneumoniae is also a
popular indicator bacteria in randomised controlled tri-
als (RCTs) as globally accepted laboratory procedures for
its detection exist [27–29] and colonisation is more
common than invasive pneumococcal disease [30–32].
The existence of internationally accepted laboratory
standards presents opportunities for between-study
comparisons.
Our aim, therefore, is to conduct a systematic review
using data from published RCTs to determine the rela-
tionship between the duration of antimicrobial exposure
and the development of, or selection for, resistance using
carriage of Streptococcus pneumoniae as an indicator or-
ganism. We will evaluate studies involving healthy indi-
viduals or patients with any illness treated with
macrolide antimicrobials in whom the development of,
or selection for, antimicrobial resistance was assessed
using Streptococcus pneumoniae carriage. We have opted
to use network meta-analysis (NMA) as the preferred
evidence synthesis method because RCTs with
head-to-head comparisons of different durations of
macrolides will likely be too rare for a meaningful
pair-wise meta-analyses. NMAs allow the use of both
direct and indirect evidence and are hence the most effi-
cient method for making inferences.
Our primary objective is to determine whether the risk
of developing macrolide resistance increases with the
duration of macrolide exposure using upper respiratory
tract carriage of Streptococcus pneumoniae as indicator
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organism. Our secondary objectives include exploring
the association between the duration of macrolide treat-
ment and (1) symptom duration, (2) treatment failure
and (3) disease recurrence.
Methods
Protocol and registration
The protocol for this planned systematic review is regis-
tered with the International Prospective Register of System-
atic Reviews (PROSPERO), CRD42018089275.
Eligibility criteria
We will include studies that fulfil the following criteria:
1. Population: healthy individuals or patients of any
illness or age, treated with macrolide antimicrobials.
We will record participant characteristics, including
age, sex and the indication for treatment.
2. Interventions: Any macrolide antimicrobial being
given as monotherapy, via any route, for respiratory
infections. We are interested in the impact of
macrolide treatment on antimicrobial resistance in
Streptococcus pneumoniae carriage. We will record
the specific macrolide, dose and duration reported
in each study. Registered macrolides include
azithromycin, clarithromycin, erythromycin,
fidaxomicin, telithromycin, carbomycin a,
josamycin, kitasamycin, midecamycin, midecamycin
acetate, oleandomycin, solithromycin, spiramycin,
troleandomycin, tylosin, tylocine and
roxithromycin.
3. Comparators: Other macrolides, other
antimicrobials, placebo, or no treatment.
Macrolides are commonly used for respiratory tract
infections, and amoxicillin and doxycycline are
expected to be the most frequent non-macrolide
comparators.
4. Outcomes: The primary outcome will be the
incidence/risk of macrolide resistance in
Streptococcus pneumoniae carriage among
individuals in whom this did not exist before
commencing macrolide treatment. Macrolide
resistance in Streptococcus pneumoniae results from
either ribosomal dimethylation by an enzyme
encoded by erm(B), efflux by a two-component efflux
pump encoded by mef (E)/mel(msr(D)), or mutations
of the ribosomal target site of macrolides [33]. We
will include studies that utilised any established
laboratory method to demonstrate evidence of
macrolide resistance.
Our secondary outcomes include the duration of
symptoms (number of symptomatic days from com-
mencement of therapy), risk of treatment failure
(persistence of symptoms after completing a dosage of
antimicrobials) and disease recurrence (re-emergence of
disease within 4 weeks of the resolution of previous
symptoms).
5. Study design: RCTs. Restricting to RCTs will
minimise confounding.
6. Language and time limitations: We will include
studies published in any language and on any date.
For articles in languages other than English that are
eligible for full-text review, we will seek assistance
from a native speaker who has been trained in data
extraction using an article published in English.
Anticipated network geometry
In NMA geometry, competing interventions are repre-
sented by points termed nodes. In this case, nodes are
the duration of exposure to any macrolide used in the
included RCTs (Fig. 1). We will classify treatment dur-
ation as brief if it is ≤ 5 days, short if it is 6 to 10 days,
and prolonged if it is > 10 days. These durations are
based on an understanding of the current clinical use of
macrolides, which are dosed for up to 5 days for com-
munity acquired pneumonia, up to 10 days for severe
pneumonia, and for prolonged periods of time for in-
flammatory respiratory illnesses such as cystic fibrosis
and non-cystic fibrosis bronchiectasis. Within the net-
work, the lines joining nodes are termed edges and are
drawn to a thickness that graphically represents the an-
ticipated amount of evidence or number of comparisons
that we expect to find between the particular nodes. For
example, it is likely that more RCTs will compare a
macrolide to a control than to another macrolide of a
different duration. NMAs will allow us to compare dif-
ferent durations of macrolide exposure (brief, short and
prolonged) by computing indirect comparisons, provided
that any patient meeting our eligibility criteria would,
theoretically, have been equally likely to be randomised
to any of the interventions of the studies included in the
network.
Information sources and search strategy
We will search for studies that meet the eligibility criteria
in MEDLINE, Embase, Global Health, Web of Science
and Cochrane Central Register of Controlled Trials (CEN-
TRAL: The Cochrane Library). MEDLINE, Embase and
Global Health will be searched using the Ovid platform.
Papers will not be excluded on the basis of the language of
publication and time frame in which they were published.
We will only include data from peer-reviewed papers in
order to ensure scientific quality.
In Table 1, we present our search strategy for MED-
LINE, which we will adapt for the other databases. This
strategy was reviewed by an information retrieval expert
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Table 1 Search strategy for MEDLINE using Ovid platform
Theme Line number Searches
Antimicrobial resistance 1. drug resista* or exp drug resistance, microbial/
2. bacterial resistan*.ti,ab.
3. antimicrobial resistan*.ti,ab.
4. 1 or 2 or 3
Macrolides 5. MACROLIDES/
6. (Azithromycin or Clarithromycin or Erythromycin or Fidaxomicin or Telithromycin or
Carbomycin A or Josamycin or Kitasamycin or Midecamycin or midecamycin acetate or
Oleandomycin or Solithromycin or Spiramycin or Troleandomycin or Tylosin or tylocine or
Roxithromycin).ti,ab.
7. 5 or 6
Antimicrobial resistance studies that use
macrolides (any design)
8. 4 and 7
MEDLINE filter for clinical trials 9. randomised controlled trial.pt.
10. controlled clinical trial.pt.
11. randomised.ab.
12. placebo.ab.
13. drug therapy.fs.
14 randomly.ab.
15. trial.ab.
16. groups.ab.
17. arms.ab.
18. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. exp animals/ not humans.sh.
20. 19 not 18
Antimicrobial resistance studies that use
macrolides in clinical trials
21. 8 and 20
Fig. 1 Hypothetical network of anticipated randomised controlled trial data for the effect of macrolide treatment duration on the development
of antimicrobial resistance. Each treatment group is a node. The lines joining nodes, termed edges, will be drawn to thickness that graphically
represents the amount of direct evidence: the number of comparisons that we expect to find between a particular pair of nodes
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from the London School of Hygiene & Tropical Medi-
cine (LSHTM) library. After running the search, we will
export results to Endnote X8 and remove all duplicates.
We will also include any relevant articles identified from
the reference lists of included articles.
Study selection
Investigator THD will implement the search strategy,
and then investigators THD and MN will screen the ti-
tles and abstracts of resulting papers against the eligibil-
ity criteria. THD and MN will independently assess the
full texts of the included papers for eligibility using the
above criteria. The main reason for non-inclusion at the
full-text stage will be documented. Investigator KF will
resolve any disagreements.
Data extraction
Publication information will be exported from Endnote
into a standardised extraction form in Microsoft Excel
Data will be extracted into (Additional file 1). This form
is currently in draft format; it will be finalised among the
study team once it has been trialled by two people
extracting the same five papers. After finalisation of the
form, two team members will extract the data independ-
ently. Discrepancies will initially be discussed and re-
solved between the two team members, with a third
team member available to resolve disputes. Multiple
publications arising from the same study will be com-
bined. Where data gaps are present, the original study
authors will be contacted. Once the extraction phase is
complete, data will be exported into the analysis
software.
Data for assessing methodological comparability of trials
In addition to the data necessary for outcome evaluation,
we will extract information on any interventions, or
study or population characteristics that may act as effect
modifiers, as is necessary for the assessment of the as-
sumptions of the NMA. These are:
1. Methods: study design, randomisation (individual or
cluster), total duration of study, number of study
centres and location, study setting, withdrawals and
date of study.
2. Participants: age, number, setting, eligibility criteria
and baseline antimicrobial resistance (AMR).
3. Interventions: indication of treatment, dose of both
the macrolide and control interventions and
duration of treatment.
4. Outcomes: authors’ primary and secondary
outcomes, timing for assessing AMR in relation to
the treatment administration schedule and
participant adherence levels. We will attempt to
extract outcome data per study arm, as opposed to
summary effects.
5. Additional factors: trial sponsorship, trial funding
and important conflicts of interest reported by the
authors.
Data from cross-over and cluster randomised trials
The units of analysis in cross-over and cluster rando-
mised trials (CRTs) need special considerations before
meta-analysis is undertaken in order to address
carry-over effects and clustering, respectively. For
cross-over studies we will only extract data from the first
period, while for CRTs, we will extract data that ac-
counts for the clustering.
Risk of bias assessment
We will conduct a risk of bias assessment at the level of
the study. We will use the revised Cochrane risk-of-bias
tool for randomised trials (RoB 2.0), the recommended
method for assessing experimental studies [34]. The risk
of bias assessment tool interrogates various aspects of
selection and information bias. It involves assessing how
the allocation sequence was generated, how it was con-
cealed, if blinding was done, how outcomes were ascer-
tained, the quality of follow up, and whether there was
selective outcome reporting. The risk of bias assessment
will be done independently by two reviewers and dis-
agreements resolved by discussion or by third reviewer.
Data analysis
Guiding counterfactual model
Our analysis will strive, as far as possible, to mimic the
counterfactual framework presented in Fig. 2. The ideal
study for addressing the primary outcome is one that re-
cruits AMR-free participants of similar demographics,
randomises them (1:1:1) to receiving any of the three du-
rations of the same macrolide antimicrobial (brief, short
and prolonged), and then follows them for the same dur-
ation before assessing for AMR using the same tech-
nique. Restricting to the same type of macrolide
antimicrobial would limit the impact of the inherent dif-
ferences in the intervention itself. For example, within
the macrolide class, the drugs have different bioavailabil-
ity and half-lives; this may impact the development of,
or selection for, resistance. Additionally, different dosing,
routes of administration, and strength of activity against
S. pneumoniae are other sources of variability. Further-
more, an optimal study would assess outcomes in each
arm at the same time relative to the end of treatment
(e.g. 1 day post-treatment), as macrolide AMR has been
shown to decrease with time from last date of treatment.
The use of the same technique would ensure compar-
ability of results between arms.
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While ideal, achieving all these factors in a real-life system-
atic review is unlikely. Our final statistical analysis plan will
therefore be a calculated trade-off of these ideal conditions.
Study and network characteristics
Data will initially be analysed using descriptive statistics,
including all the variables described above, in addition
to reporting the comparisons performed in each study,
indications for antimicrobial therapy, participant charac-
teristics, study setting, and methodological approaches.
We will prepare a network diagram (similar to the
hypothetical diagram shown in Fig. 1) in which the size
of the nodes reflect the total number of patients rando-
mised to each intervention, the thickness of edges is pro-
portional to the number of direct comparisons, and the
colour of each edge will represent the risk of bias. We
will use a contribution matrix to understand and rank
the influence of various comparisons in the network on
the final summary data [35, 36].
Pair-wise and network meta-analysis
If sufficiently methodologically homogeneous studies are
identified, we will perform pair-wise meta-analysis for the
primary outcome using either fixed effects or random ef-
fects modelling approaches, depending on the extent of
heterogeneity. We will assess the extent of heterogeneity
using the Cochran Q2 and I2 statistics. We will convey the
extent of heterogeneity visually using a forest plot.
Next, we will assess whether the identified studies meet
the assumptions for a NMA. Apart from having reason-
ably homogeneous methodologies, the key assumption for
ensuring validity of inferences drawn from indirect com-
parisons within a network is transitivity; the balance of the
distributions of patient and study characteristics across
studies. Initially, we will determine if this assumption is
fulfilled by conducting a qualitative review of the RCT
characteristics described earlier (‘Data extraction’ section).
For the subset of eligible studies in which the transitivity
assumption holds, we will assume that each of their pa-
tients were equally likely to be randomised to any of the
antimicrobial agents and treatment durations being inves-
tigated, thus establishing the basis for the indirect compar-
isons. Fixed and random effects NMAs will then be used
to synthesise all the evidence for the primary outcome
and to rank included treatments. To identify the appropri-
ate model between fixed and random effects NMAs for
our data, we will use the deviance information criteria
(DIC) to assess their goodness-of-fit. The summary effect
measures for all pairwise comparisons will be presented in
a league table. We will rank the risk of AMR with various
treatments using the surface under the cumulative ranking
curve (SUCRA) and mean ranks [37].
Consistency within the network—the agreement be-
tween direct and indirect evidence—will be assessed
within each loop of evidence using loop-specific approach
[38] and by employing a global method for evaluating the
whole network [39]. We will also estimate the I2 for net-
work heterogeneity and inconsistency [40, 41], but we will
exercise caution when interpreting the results, considering
the well-established limitations in power [42]. We will use
funnel plot to assess for publication bias.
Additional analyses
We will perform subgroup, meta-regression and sensitiv-
ity NMA analyses. The subgroup analyses will involve
running the NMA model stratified by study-level
Fig. 2 Counterfactual framework guiding analysis for the primary outcome of the systematic review
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characteristics, i.e. (1) the age groups of participants, (2)
country in which the study was conducted, (3) treatment
indications, (4) macrolide type and (5) publication calen-
dar period. The meta-regression will include the
study-level covariates described earlier (‘Data for asses-
sing methodological comparability of trials’ section), in
order to reduce heterogeneity. We will initially add the
covariates to the NMA individually, retaining those that
have a meaningful impact on the DIC and considering
combinations of factors after the initial individual-level
assessment. Should we identify additional relevant char-
acteristics during data extraction or analysis for both the
subgroup analyses and meta-regression, we will identify
such analysis (in our publication) as post hoc. In sensi-
tivity analyses, we will perform the NMA with and with-
out studies that have high risk of bias.
Model implementation
We will perform our analyses and report treatment ef-
fects on both relative and absolute difference scales, stat-
ing odds ratios (ORs), risk differences (RDs) and
respective 95% credible intervals (95%CrI) for all com-
parisons. We will model using OpenBUGS [43] and
Stata release 15 (StataCorp, College Station, TX, USA).
We will use binomial likelihoods with uninformative
prior distributions for our Bayesian modelling. The
Brooks-Gelman-Rubin diagnostic will be utilised to as-
sess for model convergence [44, 45]. We will primarily
use the mvmeta command [46] in Stata to assess incon-
sistency and to produce network graphs.
Credibility of the evidence
The credibility of the evidence will be evaluated with respect
to its limitations, indirectness, inconsistency, imprecision
and publication bias using the approach recommended by
the Grade of Recommendation, Assessment, Development
and Evaluation (GRADE) system [47, 48].
Dissemination of results
We will present the results of our analyses in a
peer-reviewed manuscript using the reporting guidance
by the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) [49] and the PRISMA Net-
work Meta-Analysis extension statement [50]. This work
will also form part of a PhD thesis for THD, which he
will submit to the LSHTM.
Discussion
Our systematic review will use published RCTs of
macrolide antimicrobials to establish the relationship be-
tween the duration of antimicrobial exposure and the
development of, or selection for, resistance using upper
respiratory tract carriage of Streptococcus pneumoniae,
isolated from patients with respiratory symptoms, as
indicator organism. This will inform the design of anti-
microbial prescriptions, treatment guidelines and the be-
haviour of both physicians and patients. This work
therefore will therefore be an important contribution to-
wards the realisation of current antimicrobial resistance
control strategies [19].
Where possible, through our secondary objectives, we
will attempt to describe the clinical outcomes associated
with different macrolide durations. Our results on these
outcomes will form the basis for future, detailed,
research.
The strengths of our review include publication of the
full protocol with PROSPERO and in this peer-reviewed
article, with detailed methodology laid out a priori. The
internal validity of our review is safeguarded by our re-
striction of the study type to RCTs. The quality and
transparency of our work are ensured by our adherence
to both PRISMA and PRISMA NMA guidelines.
The conclusions of our NMA will be weakened if dir-
ect comparisons are rare, leading to an overreliance on
indirect comparisons. Heterogeneity may be introduced
by our broad participant population (all ages, any indica-
tion of treatment), global coverage (any setting) and un-
limited study period. We will seek to limit this by adding
study-level covariates to the NMA model, if required.
To our knowledge, our review and NMA will be the
first attempt to systematically examine the association
between the duration of exposure to macrolide antimi-
crobials and subsequent development of, or selection for,
resistant Streptococcus pneumonia carriage. Therefore,
our review will not only provide direction for AMR
stewardship policies, but also guide future AMR
research.
Additional file
Additional file 1: Data extraction form. The draft form includes the risk
of bias assessment tool and documents the data which will be extracted
from included studies. (DOCX 26 kb)
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